Therapy interface: in vivo, butyrate accelerates CD8+ T-cell infiltration and synergizes with anti-PD-1 in CRC models, consistent with SCFAs’ HDAC-dependent T-cell programming [14, 91]. The gene discussed is CD8A; the disease is colorectal carcinoma.